ESF/AY/500, a polyherbal formulation intended to use for diabetic patients has been screened for antioxidant activity. For antioxidant studies, ESF/AY/500 was administered orally for 21 days at a dose of 500 mg/kg body weight to Streptozotocin induced diabetic male Wistar rats. All the animals were sacrificed on the 22nd day and the levels of LPO, SOD, CAT, GPx and GSH in kidney and liver of control and experimental rats were studied. The formulation exhibited significant antioxidant activity showing increased levels of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and reduced glutathione (GSH) and decreased level of lipid peroxidation. These results showed that treatment with ESF/AY/500 lowers Streptozotocin induced LPO and alters SOD, CAT, GPx and GSH enzymes to reduce oxidative stress
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 15261 citations as per Google Scholar report